{
    "nctId": "NCT03750240",
    "briefTitle": "Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy",
    "officialTitle": "Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "Change in Tumor Size",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with no sign of breast cancer as controls\n* Non-pregnant and non-lactating\n* Ability to understand and willingness to sign a written consent\n\nExclusion Criteria:\n\n* Contra-indications to MRI (i.e., ferromagnetic prostheses, metallic surgical implants that are not compatible with an MRI machine, claustrophobia etc.)\n* Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.\n* Pregnant or lactating women, women using hormonal treatment in the 6 months prior to the study.\n* Women with history of breast disease, previous breast surgery, or breast implants.\n* Patients with a currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for 3 years.\n* Psychiatric illness or other conditions and circumstances which could prevent the patient from being compliant with the protocol.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}